目的 探讨SLeX和Maspin表达与乳腺浸润性导管癌(BIDC)临床病理指标及预后的关系.方法 80例BIDC手术切除标本及30例距癌灶3 cm的癌旁乳腺组织,应用EliVisionTM plus免疫组织化学二步法检测SLeX和Maspin在癌组织及癌旁乳腺组织中的表达,分析SLeX和Maspin与病人年龄、TNM分期、分化等级、淋巴结宏转移、术后5年内复发转移等临床病理指标的相关性.结果 癌组织SLeX和Maspin阳性率分别为86.3％(69/80)和47.5％(38/80),癌旁乳腺组织分别为20.0％(6/30)和93.3％(28/30),差异有统计学意义(均P<0.05).SLeX和Maspin表达与年龄无关(均P>0.05).在TNM(T3+T4)期、低分化、有淋巴结宏转移和5年内复发转移病人中SLeX高表达,Maspin低表达,呈负相关(r=-0.33).结论 SLeX和Maspin与BIDC发生发展显著相关,SLeX表达上调或(和)Maspin表达下调均预示癌组织分化差、进展快、预后不良.

Objective:To investigate CK19 and COX-2 expression in papillary thyroid carcinoma (PTC) and their relationship with clinicopathologic parameters.Methods:Retrospective study of 120 consecutive patients with PTC who underwent resection from May. 2017 to Dec. 2020 was conducted. The expression of CK19 and COX-2 in 120 pieces of primary PTC tissue and 30 pieces of adjacent carcinoma tissue were detected by EliVision TM plus two-step immunohistochemical method. The relationship between the expression of CK19 and COX-2 and the clinicopathologic parameters including patient age, TI-RADS classification, TNM staging, carcinomatous infiltration, lymph node metastasis was studied. The analysis was performed using SPSS 22.0 software. The numerical data were presented as numbers and percentages, and chi-test ( χ2 test) and Pearson’s correlation were used to analyze the difference and association between two groups. P<0.05 was considered statistically significant. Results:The positive immunostaining of CK19 and COX-2 were mainly localized in the cytoplasm. The positive rates of CK19 and COX-2 were 87.50% (105/120) and 72.50% (87/120) in cancer tissues and 10.00% (3/30) and 3.33% (1/30) in paracancerous tissues, respectively, with statistically significant differences (both P<0.05 by χ2 test) . In the groups with patients aged <45 years versus ≥45 years, the CK19 positive rates were 88.16% (67/76) and 86.36% (38/44) , and the COX-2 positive rates were 69.74% (53/76) and 77.27% (34/44) , respectively. In the groups of TI-RADS (grade 4 and 5) versus grade 6, the CK19 positive rates were 85.26% (81/95) and 96.00% (24/25) , and the COX-2 positive rates were 69.47% (66/95) and 84.00% (21/25) , respectively, with no statistically significant differences between the two groups (both P>0.05) . In the groups of TNM (stage T1 and T2) versus stage T3, the CK19 positive rates were 82.28% (65/79) and 97.56% (40/41) , and the COX-2 positive rates were 65.82% (52/79) and 85.36% (35/41) , respectively. In the groups with versus without cancer infiltration, the CK19 positive rates were 94.44% (68/72) and 77.08% (37/48) , and the COX-2 positive rates were 83.33% (60/72) and 56.25% (27/48) , respectively. In the groups with versus without lymph node metastasis, the CK19 positive rates were 95.59% (65/68) and 76.92% (40/52) , and the COX-2 positive rates were 83.82% (57/68) and 57.69% (30/52) , respectively, and the differences between the above groups were statistically significant (all P<0.05 by χ2 test) . The co-positive and co-negative expression rates of CK19 and COX-2 in 120 patients were 70.83% (85/120) and 10.83% (13/120) , respectively, with a positive correlation ( r=0.45, P<0.05 by Pearson’s correlation) . Conclusions:The positive rates of CK19 and COX-2 expressions are not related to patient’s age or TI-RADS classification, but closely related to TNM stage, cancer invasion and lymph node metastasis. The up-regulation of both CK19 and COX-2 expressions predicts higher tumor stage, more aggressive invasion and more prone to lymph node metastasis.

目的 探讨COX-2和SLeX表达与甲状腺乳头状癌(PTC)临床病理指标的关系.方法 120例PTC手术切除标本,应用EliVisionTM plus免疫组化两步法检测COX-2和SLeX在癌组织及癌旁甲状腺组织中的表达,分析其在PTC组织中的表达与患者年龄(<45岁与≥45岁)、TI-RADS分类[(4类+5类)与6类]、TNM分期[(T1期+T2期)与T3期]、癌浸润(有、无)、淋巴结转移(有、无)等临床病理指标的关系.结果 COX-2阳性染色多见于细胞质,SLeX阳性染色多见于细胞膜和细胞质.癌组织COX-2和SLeX阳性率分别为72.5％和67.5％,癌旁甲状腺组织分别为3.3％和6.7％,差异均有统计学意义(P<0.05).不同年龄及TI-RADS分类中COX-2阳性率差异无统计学意义(P>0.05),不同TNM分期及是否有癌浸润、淋巴结转移中COX-2阳性率差异有统计学意义(P<0.05).不同年龄组中SLeX阳性率差异无统计学意义(P>0.05),不同TI-RADS分类、TNM分期及是否有癌浸润、淋巴结转移中SLeX阳性率差异均有统计学意义(P<0.05).120例患者COX-2和SLeX共阳性率为61.7％,共阴性率为21.7％,两者表达呈正相关(r=0.52,P<0.05).结论 COX-2和SLeX表达均与PTC患者年龄无关,SLeX表达与TI-RADS分类有关,两者表达上调均预示癌组织TNM分期晚,浸润性强,易发生淋巴结转移.

目的 探讨血清N端骨钙素(N-Osrteoc)、骨桥蛋白(OPN)、前列腺特异性抗原(PSA)联合检测在前列腺癌骨转移诊断中的价值.方法 将2016年1月至2020年4月中国人民解放军陆军第八十一集团军医院收治的93例前列腺癌患者纳入研究,根据核素骨显像检查结果分为无骨转移组(40例)和骨转移组(53例).采用罗氏CobasE411全自动电化学分析仪检测血清N-Osrteoc水平,贝克曼Access2全自动化学发光分析仪检测血清PSA水平,酶联免疫吸附法(ELISA)检测血清OPN水平,应用受试者工作特征(ROC)曲线评价上述指标用于前列腺癌骨转移诊断的价值.结果 骨转移组患者血清N-Osrteoc、OPN、PSA水平均高于无骨转移组(P<0.05).无骨转移组与骨转移组肿瘤最大径、TNM分期、浸润深度、复发与否比较,差异有统计学意义(P<0.05),且骨转移组中肿瘤最大径≥5 cm、TNM分期Ⅲ～Ⅳ期、浸润深度≥6 cm、有复发的患者比例明显高于无骨转移组(P<0.05).血清N-Osrteoc、OPN、PSA联合检测用于前列腺癌骨转移诊断的曲线下面积(AUC)、灵敏度、特异度、准确度分别为0.873、88.7％、92.5％和90.3％,均高于血清N-Osrteoc、OPN、PSA三者单独检测(P<0.05).多因素Logistic回归分析显示:TNM分期Ⅲ～Ⅳ期、高水平N-Osrteoc、OPN、PSA是前列腺癌骨转移的独立危险因素(P<0.05).结论 前列腺癌骨转移患者血清N-Osrteoc、OPN、PSA水平明显升高;N-Osrteoc、OPN联合PSA检测在前列腺癌骨转移诊断中具有较高的灵敏度、特异度,值得临床推广应用.

Objective:To investigate the expression changes of SLeX and Gal-3 in papillary thyroid carcinoma (PTC) and the relationship with clinicopathologic parameters.Methods:A retrospective study of 120 continuous patients with PTC who underwent resection from May 2017 to December 2020 was conducted. The expressions of SLeX and Gal-3 were detected in 120 pieces of primary PTC tissue and 30 pieces of adjacent carcinoma tissue by EliVisionTM plus two-step immunohistochemical method. The relationships between the expressions of SLeX and Gal-3 and the clinicopathologic parameters including patient age, TI-RADS grading, TNM staging,carcinomatous infiltration, lymph node metastasis were studied.Results:The differences of positive rates of SLeX and Gal-3 between primary PTC tissue (67.5%, 90.8% respectively) and adjacent carcinoma tissue (6.7%, 16.7% respectively) were statistically significant (both P<0.001). The expressions of SLeX had not statistically significant in the groups of different ages. The SLeX expression significantly correlated with the TI-RADS grading, TNM stages, carcinomatous infiltration, lymph node metastasis (all P<0.05). The expressions of Gal-3 had not statistically significant in the groups of different ages, TI-RADS grading, TNM stages. The Gal-3 expression significantly correlated with the carcinomatous infiltration, lymph node metastasis (both P<0.05). The rate of both positive expressions was 65.8%, and both negative expressions was 7.5%. There was a positive correlation between the expressions of SLeX and Gal-3 in PTC tissue (r=0.32, P<0.05).Conclusion:The up-regulated SLeX expression may hint high TI-RADS grading and late TNM stages. High-level expressions of SLeX and Gal-3 in PTC are closely correlated with the progress of carcinomatous infiltration and lymph node metastasis.

目的 探讨Maspin和Survivin表达与宫颈鳞状细胞癌(宫颈鳞癌)临床病理指标的关系.方法 选取2008年1月至2013年12月间陆军第81集团军医院收治的行根治性手术切除的54例宫颈鳞癌标本,采用EliVisionTM plus免疫组化2步法检测Maspin和Survivin在宫颈鳞癌组织及癌旁宫颈组织中的表达,分析宫颈鳞癌组织中的表达与患者临床病理的关系.结果 Maspin和Sur-vivin阳性染色多见于细胞质,部分可见于细胞核.癌组织及癌旁组织Maspin和Survivin阳性率比较,差异均有统计学意义(均P<0.05).宫颈鳞癌患者年龄和淋巴转移与Maspin表达阳性率无关(P>0.05);患者癌灶最大径、间质浸润深度、分化程度、TNM分期和术后5年内复发转移均与Maspin表达阳性率相关.患者年龄和癌灶最大径与Survivin表达阳性率无关(P>0.05);患者间质浸润深度、分化程度、TNM分期、淋巴转移和术后5年内复发转移均与Survivin表达阳性率相关(均P<0.05).Maspin和Survivin同时阳性者9例,同时阴性者4例,Maspin阳性、Survivin阴性者11例,Maspin阴性、Survivin阳性者30例,两者呈负相关(r=-0.33,P<0.05).结论 Maspin和Survivin与宫颈鳞癌的发生发展密切相关,Maspin表达下调和(或)Survivin表达上调均预示癌组织分化差、进展快,预后不良.

目的 探讨Ets-1在宫颈鳞状细胞癌组织的表达及其与临床病理因素的关系.方法 收集中国人民解放军第二五一医院2008年1月-2013年12月宫颈鳞状细胞癌根治性手术切除标本54例,应用EliVisionTM plus免疫组织化学染色两步法检测癌组织及癌旁组织中Ets-1的表达状况,探讨与患者年龄、癌灶直径、癌细胞间质浸润深度、分化程度、TNM分期、术前淋巴结转移及术后5年内复发转移的关系.结果 Ets-1在癌组织表达阳性率为64.8％(35/54),在癌旁组织表达阳性率为13.3％(4/30),差异有统计学意义(P＜0.05).根据患者年龄及癌灶直径分组,组间Ets-1表达阳性率差异均无统计学意义(均P＞0.05);根据癌细胞间质浸润深度、分化程度、TNM分期、术前有无淋巴结转移、术后5年内复发转移及Ki-67表达强度分组,组间Ets-1表达阳性率差异均有统计学意义(均P＜0.05).结论 Ets-1参与了宫颈鳞状细胞癌的发生发展,其表达上调提示癌组织恶性程度高、进展快及预后差.

目的 探讨maspin在宫颈鳞状细胞癌(简称宫颈鳞癌)组织中的表达及其临床病理意义.方法 选取宫颈鳞癌根治性手术切除标本72例,应用免疫组化染色EliVisionTM plus两步法检测癌组织及癌旁组织maspin的表达,分析其与患者年龄、术前淋巴结转移、癌灶最大径、癌细胞间质浸润深度、分化程度、TNM分期及术后5年内复发转移的关系.结果 癌组织maspin阳性率为37.5％ (27/72),癌旁组织maspin阳性率为70.0％ (21/30),差异有统计学意义(P＜0.05);Maspin阳性率在不同年龄及术前有无淋巴结转移组间差异均无统计学意义(P＞0.05);按照癌灶最大径、癌细胞间质浸润深度、分化程度、TNM分期、Ki-67表达指数5项临床病理指标分组,maspin阳性率差异均有统计学意义(P＜0.05);Maspin阳性率在术后5年内有复发转移与无复发转移组间差异亦有统计学意义(P＜0.05).结论 Maspin表达下调不仅有助于鉴别宫颈良恶性病变,而且提示宫颈鳞癌恶性程度高、进展速度快、患者预后差.

目的 探讨宫颈鳞状细胞癌组织M aspin和Ets-1的表达及其与临床病理因素的关系.方法 收集原中国人民解放军第二五一医院,2008年1月至2013年12月,宫颈鳞状细胞癌根治性手术切除标本54例,应用EliVisionTM plus免疫组织化学染色两步法检测癌组织及癌旁组织中Maspin和Ets-1的表达状况,探讨它们与患者年龄、癌灶直径、癌细胞间质浸润深度、分化程度、TNM分期、术前淋巴结转移及术后5年内复发转移的关系.结果 Maspin和Ets-1在癌组织表达阳性率分别为37.0％(20/54)和64.8％ (35/54),在癌旁组织表达阳性率分别为70.0％ (21/30)和13.3％ (4/30),差异均有统计学意义(x2值分别为8.387、20.550,均P＜0.05).根据患者年龄及术前有无淋巴结转移分组,组间Maspin表达阳性率差异均无统计学意义(x2值分别为0.120、0.675,均P＞0.05);根据癌灶直径、癌细胞间质浸润深度、分化程度、TNM分期、术后5年内复发转移及Ki-67表达强度分组,组间Maspin表达阳性率差异均有统计学意义(x2值分别为5.050、12.452、6.277、6.710、5.004、5.660,均P＜0.05).根据患者年龄及癌灶直径分组,组间Ets-1表达阳性率差异均无统计学意义(x2值分别为0.323、0.000,均P＞0.05);根据癌细胞间质浸润深度、分化程度、TNM分期、术前有无淋巴结转移、术后5年内复发转移及Ki-67表达强度分组,组间Ets-1表达阳性率差异均有统计学意义(x2值分别为8.591、8.489、4.913、5.675、7.407、4.707,均P＜0.05).两者在宫颈鳞状细胞癌组织中的表达呈负相关(r=-0.30,P＜0.05).结论 Maspin和Ets-1与宫颈鳞状细胞癌的发生发展密切相关,Maspin表达下调和Ets-1表达上调均提示癌组织恶性程度高、进展快、预后差.